Redeye comments on Scandion Oncology’s Q1 2023 report, which follows a first quarter where the company delivered PANTAX phase Ib top-line data, which aligned with our expectations. We judge that CORIST part 4 data is the primary catalyst for the company’s share in the coming 12-18 months. We do some housekeeping in our model and update our estimates and valuation.